Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes
• Independent dose recalculation based PSQA is applied in clinics. • Means to assess PSQA results from clinical perspective are made available. • Proposed PSQA allows to verify patient selection for model-based clinics.
Gespeichert in:
| Autor*in: |
Meijers, Arturs [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2020 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
6 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells - Han, Xiaobing ELSEVIER, 2021, journal of the European Society for Therapeutic Radiology and Oncology, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:150 ; year:2020 ; pages:136-141 ; extent:6 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.radonc.2020.06.027 |
|---|
| Katalog-ID: |
ELV051573008 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV051573008 | ||
| 003 | DE-627 | ||
| 005 | 20230624174805.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210910s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.radonc.2020.06.027 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001395.pica |
| 035 | |a (DE-627)ELV051573008 | ||
| 035 | |a (ELSEVIER)S0167-8140(20)30352-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 570 |a 540 |q VZ |
| 100 | 1 | |a Meijers, Arturs |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes |
| 264 | 1 | |c 2020 | |
| 300 | |a 6 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • Independent dose recalculation based PSQA is applied in clinics. • Means to assess PSQA results from clinical perspective are made available. • Proposed PSQA allows to verify patient selection for model-based clinics. | ||
| 650 | 7 | |a Predicted outcomes |2 Elsevier | |
| 650 | 7 | |a Treatment delivery log files |2 Elsevier | |
| 650 | 7 | |a Patient specific quality assurance |2 Elsevier | |
| 650 | 7 | |a Proton therapy |2 Elsevier | |
| 700 | 1 | |a Guterres Marmitt, Gabriel |4 oth | |
| 700 | 1 | |a Ng Wei Siang, Kelvin |4 oth | |
| 700 | 1 | |a van der Schaaf, Arjen |4 oth | |
| 700 | 1 | |a Knopf, Antje C. |4 oth | |
| 700 | 1 | |a Langendijk, Johannes A. |4 oth | |
| 700 | 1 | |a Both, Stefan |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Han, Xiaobing ELSEVIER |t Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |d 2021 |d journal of the European Society for Therapeutic Radiology and Oncology |g Amsterdam [u.a.] |w (DE-627)ELV00004122X |
| 773 | 1 | 8 | |g volume:150 |g year:2020 |g pages:136-141 |g extent:6 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.radonc.2020.06.027 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 150 |j 2020 |h 136-141 |g 6 | ||
| author_variant |
a m am |
|---|---|
| matchkey_str |
meijersartursguterresmarmittgabrielngwei:2020----:esbltoptetpcfcultasrneopooteayaeoidpnetoea |
| hierarchy_sort_str |
2020 |
| publishDate |
2020 |
| allfields |
10.1016/j.radonc.2020.06.027 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001395.pica (DE-627)ELV051573008 (ELSEVIER)S0167-8140(20)30352-2 DE-627 ger DE-627 rakwb eng 570 540 VZ Meijers, Arturs verfasserin aut Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes 2020 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Independent dose recalculation based PSQA is applied in clinics. • Means to assess PSQA results from clinical perspective are made available. • Proposed PSQA allows to verify patient selection for model-based clinics. Predicted outcomes Elsevier Treatment delivery log files Elsevier Patient specific quality assurance Elsevier Proton therapy Elsevier Guterres Marmitt, Gabriel oth Ng Wei Siang, Kelvin oth van der Schaaf, Arjen oth Knopf, Antje C. oth Langendijk, Johannes A. oth Both, Stefan oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:150 year:2020 pages:136-141 extent:6 https://doi.org/10.1016/j.radonc.2020.06.027 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 150 2020 136-141 6 |
| spelling |
10.1016/j.radonc.2020.06.027 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001395.pica (DE-627)ELV051573008 (ELSEVIER)S0167-8140(20)30352-2 DE-627 ger DE-627 rakwb eng 570 540 VZ Meijers, Arturs verfasserin aut Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes 2020 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Independent dose recalculation based PSQA is applied in clinics. • Means to assess PSQA results from clinical perspective are made available. • Proposed PSQA allows to verify patient selection for model-based clinics. Predicted outcomes Elsevier Treatment delivery log files Elsevier Patient specific quality assurance Elsevier Proton therapy Elsevier Guterres Marmitt, Gabriel oth Ng Wei Siang, Kelvin oth van der Schaaf, Arjen oth Knopf, Antje C. oth Langendijk, Johannes A. oth Both, Stefan oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:150 year:2020 pages:136-141 extent:6 https://doi.org/10.1016/j.radonc.2020.06.027 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 150 2020 136-141 6 |
| allfields_unstemmed |
10.1016/j.radonc.2020.06.027 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001395.pica (DE-627)ELV051573008 (ELSEVIER)S0167-8140(20)30352-2 DE-627 ger DE-627 rakwb eng 570 540 VZ Meijers, Arturs verfasserin aut Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes 2020 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Independent dose recalculation based PSQA is applied in clinics. • Means to assess PSQA results from clinical perspective are made available. • Proposed PSQA allows to verify patient selection for model-based clinics. Predicted outcomes Elsevier Treatment delivery log files Elsevier Patient specific quality assurance Elsevier Proton therapy Elsevier Guterres Marmitt, Gabriel oth Ng Wei Siang, Kelvin oth van der Schaaf, Arjen oth Knopf, Antje C. oth Langendijk, Johannes A. oth Both, Stefan oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:150 year:2020 pages:136-141 extent:6 https://doi.org/10.1016/j.radonc.2020.06.027 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 150 2020 136-141 6 |
| allfieldsGer |
10.1016/j.radonc.2020.06.027 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001395.pica (DE-627)ELV051573008 (ELSEVIER)S0167-8140(20)30352-2 DE-627 ger DE-627 rakwb eng 570 540 VZ Meijers, Arturs verfasserin aut Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes 2020 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Independent dose recalculation based PSQA is applied in clinics. • Means to assess PSQA results from clinical perspective are made available. • Proposed PSQA allows to verify patient selection for model-based clinics. Predicted outcomes Elsevier Treatment delivery log files Elsevier Patient specific quality assurance Elsevier Proton therapy Elsevier Guterres Marmitt, Gabriel oth Ng Wei Siang, Kelvin oth van der Schaaf, Arjen oth Knopf, Antje C. oth Langendijk, Johannes A. oth Both, Stefan oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:150 year:2020 pages:136-141 extent:6 https://doi.org/10.1016/j.radonc.2020.06.027 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 150 2020 136-141 6 |
| allfieldsSound |
10.1016/j.radonc.2020.06.027 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001395.pica (DE-627)ELV051573008 (ELSEVIER)S0167-8140(20)30352-2 DE-627 ger DE-627 rakwb eng 570 540 VZ Meijers, Arturs verfasserin aut Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes 2020 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • Independent dose recalculation based PSQA is applied in clinics. • Means to assess PSQA results from clinical perspective are made available. • Proposed PSQA allows to verify patient selection for model-based clinics. Predicted outcomes Elsevier Treatment delivery log files Elsevier Patient specific quality assurance Elsevier Proton therapy Elsevier Guterres Marmitt, Gabriel oth Ng Wei Siang, Kelvin oth van der Schaaf, Arjen oth Knopf, Antje C. oth Langendijk, Johannes A. oth Both, Stefan oth Enthalten in Elsevier Science Han, Xiaobing ELSEVIER Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells 2021 journal of the European Society for Therapeutic Radiology and Oncology Amsterdam [u.a.] (DE-627)ELV00004122X volume:150 year:2020 pages:136-141 extent:6 https://doi.org/10.1016/j.radonc.2020.06.027 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA AR 150 2020 136-141 6 |
| language |
English |
| source |
Enthalten in Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells Amsterdam [u.a.] volume:150 year:2020 pages:136-141 extent:6 |
| sourceStr |
Enthalten in Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells Amsterdam [u.a.] volume:150 year:2020 pages:136-141 extent:6 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Predicted outcomes Treatment delivery log files Patient specific quality assurance Proton therapy |
| dewey-raw |
570 |
| isfreeaccess_bool |
false |
| container_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| authorswithroles_txt_mv |
Meijers, Arturs @@aut@@ Guterres Marmitt, Gabriel @@oth@@ Ng Wei Siang, Kelvin @@oth@@ van der Schaaf, Arjen @@oth@@ Knopf, Antje C. @@oth@@ Langendijk, Johannes A. @@oth@@ Both, Stefan @@oth@@ |
| publishDateDaySort_date |
2020-01-01T00:00:00Z |
| hierarchy_top_id |
ELV00004122X |
| dewey-sort |
3570 |
| id |
ELV051573008 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV051573008</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624174805.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.radonc.2020.06.027</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001395.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV051573008</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-8140(20)30352-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Meijers, Arturs</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Independent dose recalculation based PSQA is applied in clinics. • Means to assess PSQA results from clinical perspective are made available. • Proposed PSQA allows to verify patient selection for model-based clinics.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Predicted outcomes</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Treatment delivery log files</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Patient specific quality assurance</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Proton therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guterres Marmitt, Gabriel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ng Wei Siang, Kelvin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van der Schaaf, Arjen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Knopf, Antje C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Langendijk, Johannes A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Both, Stefan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Han, Xiaobing ELSEVIER</subfield><subfield code="t">Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells</subfield><subfield code="d">2021</subfield><subfield code="d">journal of the European Society for Therapeutic Radiology and Oncology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00004122X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:150</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:136-141</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.radonc.2020.06.027</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">150</subfield><subfield code="j">2020</subfield><subfield code="h">136-141</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| author |
Meijers, Arturs |
| spellingShingle |
Meijers, Arturs ddc 570 Elsevier Predicted outcomes Elsevier Treatment delivery log files Elsevier Patient specific quality assurance Elsevier Proton therapy Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes |
| authorStr |
Meijers, Arturs |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV00004122X |
| format |
electronic Article |
| dewey-ones |
570 - Life sciences; biology 540 - Chemistry & allied sciences |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
570 540 VZ Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes Predicted outcomes Elsevier Treatment delivery log files Elsevier Patient specific quality assurance Elsevier Proton therapy Elsevier |
| topic |
ddc 570 Elsevier Predicted outcomes Elsevier Treatment delivery log files Elsevier Patient specific quality assurance Elsevier Proton therapy |
| topic_unstemmed |
ddc 570 Elsevier Predicted outcomes Elsevier Treatment delivery log files Elsevier Patient specific quality assurance Elsevier Proton therapy |
| topic_browse |
ddc 570 Elsevier Predicted outcomes Elsevier Treatment delivery log files Elsevier Patient specific quality assurance Elsevier Proton therapy |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
m g g mg mgg w s k n wsk wskn d s a v dsa dsav a c k ac ack j a l ja jal s b sb |
| hierarchy_parent_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| hierarchy_parent_id |
ELV00004122X |
| dewey-tens |
570 - Life sciences; biology 540 - Chemistry |
| hierarchy_top_title |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV00004122X |
| title |
Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes |
| ctrlnum |
(DE-627)ELV051573008 (ELSEVIER)S0167-8140(20)30352-2 |
| title_full |
Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes |
| author_sort |
Meijers, Arturs |
| journal |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| journalStr |
Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
500 - Science |
| recordtype |
marc |
| publishDateSort |
2020 |
| contenttype_str_mv |
zzz |
| container_start_page |
136 |
| author_browse |
Meijers, Arturs |
| container_volume |
150 |
| physical |
6 |
| class |
570 540 VZ |
| format_se |
Elektronische Aufsätze |
| author-letter |
Meijers, Arturs |
| doi_str_mv |
10.1016/j.radonc.2020.06.027 |
| dewey-full |
570 540 |
| title_sort |
feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes |
| title_auth |
Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes |
| abstract |
• Independent dose recalculation based PSQA is applied in clinics. • Means to assess PSQA results from clinical perspective are made available. • Proposed PSQA allows to verify patient selection for model-based clinics. |
| abstractGer |
• Independent dose recalculation based PSQA is applied in clinics. • Means to assess PSQA results from clinical perspective are made available. • Proposed PSQA allows to verify patient selection for model-based clinics. |
| abstract_unstemmed |
• Independent dose recalculation based PSQA is applied in clinics. • Means to assess PSQA results from clinical perspective are made available. • Proposed PSQA allows to verify patient selection for model-based clinics. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes |
| url |
https://doi.org/10.1016/j.radonc.2020.06.027 |
| remote_bool |
true |
| author2 |
Guterres Marmitt, Gabriel Ng Wei Siang, Kelvin van der Schaaf, Arjen Knopf, Antje C. Langendijk, Johannes A. Both, Stefan |
| author2Str |
Guterres Marmitt, Gabriel Ng Wei Siang, Kelvin van der Schaaf, Arjen Knopf, Antje C. Langendijk, Johannes A. Both, Stefan |
| ppnlink |
ELV00004122X |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth |
| doi_str |
10.1016/j.radonc.2020.06.027 |
| up_date |
2024-07-06T20:38:19.466Z |
| _version_ |
1803863509661908992 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV051573008</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624174805.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210910s2020 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.radonc.2020.06.027</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001395.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV051573008</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0167-8140(20)30352-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Meijers, Arturs</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Feasibility of patient specific quality assurance for proton therapy based on independent dose calculation and predicted outcomes</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2020</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• Independent dose recalculation based PSQA is applied in clinics. • Means to assess PSQA results from clinical perspective are made available. • Proposed PSQA allows to verify patient selection for model-based clinics.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Predicted outcomes</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Treatment delivery log files</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Patient specific quality assurance</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Proton therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Guterres Marmitt, Gabriel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ng Wei Siang, Kelvin</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">van der Schaaf, Arjen</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Knopf, Antje C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Langendijk, Johannes A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Both, Stefan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Han, Xiaobing ELSEVIER</subfield><subfield code="t">Identification of proteins related with pemetrexed resistance by iTRAQ and PRM-based comparative proteomic analysis and exploration of IGF2BP2 and FOLR1 functions in non-small cell lung cancer cells</subfield><subfield code="d">2021</subfield><subfield code="d">journal of the European Society for Therapeutic Radiology and Oncology</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV00004122X</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:150</subfield><subfield code="g">year:2020</subfield><subfield code="g">pages:136-141</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.radonc.2020.06.027</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">150</subfield><subfield code="j">2020</subfield><subfield code="h">136-141</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| score |
7.398221 |